» Articles » PMID: 25072677

Factors Affecting Noncompliance with Buprenorphine Maintenance Treatment

Overview
Journal J Addict Med
Specialty Psychiatry
Date 2014 Jul 30
PMID 25072677
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The current study aimed to identify risk factors for treatment noncompliance in a sample of veterans receiving buprenorphine/naloxone for an opioid use disorder.

Methods: Records from all patients who are currently or had previously been maintained on buprenorphine in the buprenorphine maintenance treatment program at the Atlanta VA Medical Center during the years 2006 to 2013 were evaluated. Of the 209 patients treated in the clinic between 2006 and 2013, 140 were excluded from the study because they did not have a call-back done at the time of data collection. Thus, 69 patient charts were selected for review.

Results: The multiple linear regression analysis of the predictable variables for noncompliance with the buprenorphine pill count showed that positive urine drug screen (UDS) for marijuana, benzodiazepines, and being a smoker (F = 3.08; P = 0.03) are significantly associated with noncompliance with buprenorphine pill count.Also, the multiple linear regression analysis of the predictable variables for noncompliance with the buprenorphine pill count showed that the psychiatric comorbidity independently (F = 4.88; P = 0.03) is significantly associated with noncompliance with buprenorphine pill count.

Conclusions: Patients found to be noncompliant were more likely to suffer from comorbid psychiatric illness. Patients who tested positive for benzodiazepines or cannabis were more likely to be noncompliant with treatment. Although the rate of noncompliance (inaccurate pill count) was high, patients were still found to be taking their prescribed buprenorphine as evidenced by positive UDS for buprenorphine/norbuprenorphine. In addition, our sample had a high rate of negative UDS screens for opioids and cocaine.

Citing Articles

Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.

Hooker S, Starkey C, Bart G, Rossom R, Kane S, Olson A BMC Prim Care. 2024; 25(1):361.

PMID: 39394565 PMC: 11468455. DOI: 10.1186/s12875-024-02609-9.


Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial.

McPherson S, Smith C, Hall L, Miguel A, Bowden T, Keever A Drug Alcohol Depend. 2024; 256:111099.

PMID: 38306822 PMC: 10923156. DOI: 10.1016/j.drugalcdep.2024.111099.


Investigating social deprivation and comorbid mental health diagnosis as predictors of treatment access among patients with an opioid use disorder using substance use services: a prospective cohort study.

Adams E, Yang J, ODonnell A, Minot S, Osborn D, Kirkbride J Subst Abuse Treat Prev Policy. 2023; 18(1):59.

PMID: 37884952 PMC: 10605983. DOI: 10.1186/s13011-023-00568-5.


Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability.

Smith C, Keever A, Bowden T, Olson K, Rodin N, McDonell M JMIR Form Res. 2023; 7:e40437.

PMID: 37074780 PMC: 10157459. DOI: 10.2196/40437.


Assessing the feasibility, usability and acceptability of the platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial.

Janzow G, Harding C, Flores M, Borodovsky J, Steinkamp J, Marsch L Drug Alcohol Depend Rep. 2023; 3:100045.

PMID: 36845988 PMC: 9949338. DOI: 10.1016/j.dadr.2022.100045.